angiotensin ii has been researched along with Left Ventricular Dysfunction in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (17.71) | 18.2507 |
| 2000's | 38 (39.58) | 29.6817 |
| 2010's | 35 (36.46) | 24.3611 |
| 2020's | 6 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, C; Cheng, J; Hao, P; Sui, W; Wang, X; Xing, Y; Xue, F; Zhang, C; Zhang, J; Zhang, M; Zhang, Y | 1 |
| Bishop, E; Bordas, M; Chowdhury, SR; Cossette, SM; Gupta, A; Harmann, LM; Kumar, SN; Lu, Q; Pan, AY; Ramchandran, R; Simpson, PM; Sonin, DL; Spearman, AD; Strande, JL; Thirugnanam, K; Zou, MH | 1 |
| Kang, W; Liu, C; Lu, H; Qiao, X; Yang, X; Zhang, S; Zhou, Z | 1 |
| Chen, Y; Du, J; Jia, MZ; Liu, Y; Ning, ZP; Qi, YF; Ren, JL; Tang, CS; Yu, YR; Zhang, LS; Zhang, YR | 1 |
| Chai, CY; Chen, IC; Dai, ZK; Hsu, JH; Lin, JY; Liu, YC; Wu, BN; Yeh, JL | 1 |
| Dehe, L; Habazettl, H; Mousa, SA; Nordine, M; Schäfer, M; Schluchter, H; Shakibaei, M; Shaqura, M; Treskatsch, S; von Kwiatkowski, P | 1 |
| Chai, D; Chen, X; Chu, Y; Du, H; Lin, J; Lin, X; Liu, J; Ma, K; Ruan, Q; Xie, H; Xu, C; Zeng, J; Zhang, H; Zhang, Y | 1 |
| Fukamizu, A; Ho, L; Imai, Y; Ishida, J; Ito, H; Kadowaki, A; Kimura, A; Kuba, K; Penninger, JM; Reversade, B; Sato, C; Sato, T; Watanabe, H; Yamaguchi, T | 1 |
| Chen, W; Chen, X; Huang, F; Khan, A; Li, L; Qiu, Z; Wang, L; Wang, X; Zhang, J | 1 |
| Guo, L; Han, S; He, W; Li, H; Shen, D; Wang, J; Zhang, Y | 1 |
| Divorty, N; Graham, D; Milligan, G; Nicklin, SA | 1 |
| Agarwal, H; Barthwal, MK; Reddy, SS | 1 |
| Brenes-Castro, D; Castillo, EC; García-Rivas, G; Torre-Amione, G; Vázquez-Garza, E | 1 |
| Ahmad, S; da Silva, JS; Ferrario, CM; Groban, L; Sudo, RT; Sun, X; Varagic, J; Wang, H; Zapata-Sudo, G | 1 |
| Fu, NK; Lu, FM; Wu, DY; Xu, J; Zhang, YY | 1 |
| Hu, C; Huang, Y; Jiang, M; Lin, J; Tang, J; Wu, D; Wu, L; Zhang, X | 1 |
| Alakoski, T; Kerkelä, R; Kivirikko, KI; Lipson, KE; Magga, J; Piuhola, J; Ruskoaho, H; Signore, P; Szabó, Z; Ulvila, J; Vainio, L; Vuolteenaho, O | 1 |
| Marston, S; Smoktunowicz, N; Song, W; Wilkinson, R | 1 |
| Bhimaraj, A; Celis, R; Cordero-Reyes, AM; Estep, JD; Flores-Arredondo, JH; Hamilton, DJ; Orrego, CM; Torre-Amione, G; Trevino, AR; Youker, KA | 1 |
| Aoki, T; Ikeda, S; Kadomatsu, K; Kikuchi, N; Kurosawa, R; Miyata, S; Mukherjee, R; Nogi, M; Numano, K; Omura, J; Otsuki, T; Satoh, K; Satoh, T; Shimokawa, H; Spinale, FG; Sugimura, K; Sunamura, S; Suzuki, K; Tatebe, S | 1 |
| Antunes, TT; Callera, GE; He, Y; Ryazanov, AG; Ryazanova, LV; Shrier, A; Stewart, DJ; Touyz, RM; Yogi, A; Zhai, A | 1 |
| Ahmad, S; Alencar, A; da Silva, J; Ferrario, CM; Groban, L; Lin, MR; Sun, X; Wang, H; Zapata-Sudo, G | 1 |
| Chen, YH; Hou, JW; Li, CY; Li, YG; Wang, H; Wang, Q; Wang, YP | 1 |
| Basu, R; Fan, D; Fernandez-Patron, C; Kassiri, Z; Oudit, GY; Patel, V; Samokhvalov, V; Seubert, JM; Shen, M; Takawale, A; Wang, X | 1 |
| Fujita, T; Kaneko, T; Matsui, H; Ogura, S; Shimosawa, T; Takenaka, K; Uetake, Y; Wang, H; Yatomi, Y | 1 |
| Jugdutt, BI; Konig, A; Liu, P; Moe, G | 1 |
| Dohi, K; Fujimoto, N; Imanaka-Yoshida, K; Ito, M; Kurita, T; Nobori, T; Onishi, K; Takamura, T; Tanigawa, T; Wada, H | 1 |
| Huang, BS; Leenen, FH | 1 |
| Imaizumi, T; Kai, H; Kajimoto, H; Kudo, H; Takayama, N; Yasuoka, S | 1 |
| Ardanaz, N; Carretero, OA; Cifuentes, ME; Haurani, MJ; Jackson, KW; Liao, TD; Pagano, PJ; Yang, XP | 1 |
| Ahmad, S; Brosnihan, KB; Chappell, MC; Ferrario, CM; Gallagher, PE; Groban, L; Tallant, EA; Varagic, J | 1 |
| Brubaker, PH; Kitzman, DW; Moore, JB; Stewart, KP; Wesley, DJ | 1 |
| Kong, XQ; Liu, YL; Wang, LX; Wang, XH; Wang, YL | 1 |
| Asselin, C; Bouly, M; Brand, G; Busseuil, D; Des Rosiers, C; Gillis, MA; Latour, JG; Leung, TK; Mecteau, M; Rhéaume, E; Roméo, P; Shi, Y; Tardif, JC; Thorin, E | 1 |
| Aro, J; Leskinen, H; Levijoki, J; Manninen, A; Moilanen, AM; Mustonen, E; Ruskoaho, H; Rysä, J; Serpi, R; Tokola, H; Vuolteenaho, O | 1 |
| Chen, J; Entman, ML; Lin, SC; Miao, Y; Taffet, GE; Wang, Y; Xu, J | 1 |
| Aubin, MC; Carrier, M; Forcillo, J; Maltais, S; Perrault, LP; Shi, YF; Tardif, JC | 1 |
| Hirooka, Y; Kishi, T; Ogawa, K; Sunagawa, K | 1 |
| Chagas, C; Groban, L; Jessup, JA; Lin, MS; Lindsey, SH; Wang, H | 1 |
| Fujisawa, G; Iwazu, Y; Kimura, M; Kobayashi, E; Kobayashi, T; Kusano, E; Masuda, T; Murakami, T; Muto, S; Nonaka-Sarukawa, M; Sasaki, N; Shimada, K; Shinohara, M; Watanabe, Y | 1 |
| Collier, P; McDonald, KM | 1 |
| Amaram, JS; Hillerson, D; Raizada, V; Skipper, B | 1 |
| Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C | 1 |
| Feng, S; Lu, C; Lu, Y; Pan, Z; Ren, J; Shan, H; Sun, X; Wang, J; Wang, N; Wang, Y; Xie, L; Yang, B; Yuan, Y; Zhang, Y | 1 |
| Becher, PM; Fröhlich, M; Hoffmann, S; Lindner, D; Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D; Xia, Y | 1 |
| Chen, B; Chen, Y; Dong, Y; Liu, D; Ma, Y; Xiong, Z; Yang, Y; Zhang, C | 1 |
| Ge, J; Guo, J; Jiang, G; Li, L; Wang, S; Wu, J; You, J; Zou, Y | 1 |
| Ban, T; Komeda, M; Nagata, K; Nakai, A; Nishizawa, J | 1 |
| Hamada, M; Hara, Y; Hiwada, K; Ohtsuka, T; Shigematsu, Y | 1 |
| Morena Valenzuela, Gde L; Nicolás Ruiz, F; Pascual Figal, DA; Ruipérez Abizanda, JA; Tovar Zapata, I; Valdés Chávarri, M | 1 |
| Dendorfer, A; Dominiak, P; Hartmann, F; Jain, D; Katus, H; Kurz, T; Raasch, W; Richardt, G; Schäfer, U; Tölg, R | 1 |
| Manohar, P; Piña, IL | 1 |
| Albåge, A; Berglund, H; Kennebäck, G; van der Linden, J | 1 |
| Isono, T; Kinoshita, M; Matsumoto, T; Ohnishi, M; Tsutamoto, T; Wada, A | 1 |
| Liu, P; Matsuzaki, M; Moe, G; Naik, G; Nakamura, H; Takata, S; Umemoto, S | 1 |
| Endoh, S; Hayashi, T; Kitaura, Y; Mori, T; Okabe, M; Shimomura, H; Sohmiya, K; Terasaki, F; Ukimura, A | 1 |
| Egashira, K; Hayashidani, S; Ikeuchi, M; Matsusaka, H; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J | 1 |
| Ganten, D; Huang, BS; Leenen, FH; Wang, H | 1 |
| Azizi, M; Ménard, J | 1 |
| Dzau, VJ; McMurray, JJ; Pfeffer, MA; Swedberg, K | 1 |
| Berr, SS; Bishop, SP; Bove, CM; Dimaria, JM; Epstein, FH; French, BA; Gilson, WD; Kramer, CM; Scott, CD; Yang, Z | 1 |
| Bennett, CD; Carter, CS; Chappell, MC; Groban, L; Kitzman, DW; Pailes, NA; Sonntag, WE | 1 |
| Abe, Y; Guo, P; Ishizawa, M; Kimura, S; Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Nagai, Y; Namba, T; Nishiyama, A; Noma, T; Ohmori, K; Rahman, M | 1 |
| Bissessor, N; White, H | 1 |
| Fujita, K; Funahashi, T; Hibuse, T; Hiuge, A; Kihara, S; Kurata, A; Maeda, N; Nishida, M; Nishizawa, H; Ohashi, K; Shimomura, I; Sonoda, M | 1 |
| Adrahtas, A; Cantwell, DM; Kompa, AR; Krum, H; Lewis, DA; See, F; Wang, BH | 1 |
| Ahmad, M; Huang, BS; Leenen, FH; Tan, J; White, R | 1 |
| Brilla, CG; Maisch, B; Rupp, H; Weber, KT; Zhou, G | 1 |
| Dzau, VJ; Gibbons, GH; Pratt, R | 1 |
| Angus, JA; Jennings, G; Kaye, DM | 1 |
| Kawai, H; Yokota, Y; Yokoyama, M | 1 |
| Pitt, B; Timmis, AD | 1 |
| Sigurdsson, A; Swedberg, K | 1 |
| Cleland, JG; Morgan, K | 1 |
| Lerch, R; Montessuit, C | 1 |
| Weber, KT | 1 |
| Ball, SG; Hall, AS; Megarry, SG; Sapsford, R | 1 |
| Avezum, A; Held, P; Latini, R; Lindgren, E; Maggioni, AP; McKelvie, RS; Pogue, J; Probstfield, J; Rouleau, JL; Teo, KK; Tsuyuki, RT; Wang, Y; White, M; Wiecek, EM; Yusuf, S | 1 |
| Bartels, GL; Kruijssen, DA; Remme, WJ; Van Den Heuvel, AF; van der Ent, M; van Veldhuisen, DJ | 1 |
| Bernareggi, M; Berti, F; De Gennaro Colonna, V; Müller, EE; Polvani, GL; Rossoni, G | 1 |
| He, J; Li, J; Yu, G; Zhuang, H | 1 |
| Bartels, GL; Remme, WJ; van den Heuvel, FM; van der Ent, M; van Veldhuisen, DJ | 1 |
| Fujii, M; Hayashi, M; Hisanaga, T; Horie, H; Kinoshita, M; Mabuchi, N; Maeda, K; Ohnishi, M; Sawaki, M; Sugimoto, Y; Tsutamoto, T; Wada, A | 1 |
| Bosso, FJ; Jarjoura, DG; Pilati, CF | 1 |
| Heras, M; Jiménez, W; Morales, M; Orús, J; Perez-Villa, F; Roig, E; Sanz, G | 1 |
| Aihara, Y; Kanda, T; Kobayashi, I; Kurabayashi, M; Nagai, R; Ono, Z; Sakamaki, T; Sekiguchi, K; Tanaka, T; Toyama, T; Yokoyama, T | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG | 1 |
| Anversa, P; Di Somma, S; Kajstura, J; Leri, A; Li, B; Liu, Y | 1 |
| Ito, S; Matsuoka, M; Mishiro, Y; Oki, T; Onose, Y; Tabata, T; Wakatsuki, T; Yamada, H | 1 |
| Chen, YF; Dell'Italia, LJ; Lucchesi, P; Mori, T; Oparil, S; Perry, GJ; Wei, CC; Xu, XY | 1 |
| Burnett , JC; Grande, JP; Hart, CY; Housmans, PR; Meyer, DM; Redfield, MM; Tazelaar, HD | 1 |
| Aubert, ML; Blum, WF; Dietz, R; Höhnel, K; Langenickel, T; Nüssler, AK; Pagel, I; Philipp, S; Willenbrock, R | 1 |
| Andersen, UB; Dige-Petersen, H; Ibsen, H; Rokkedal, J; Steensgaard-Hansen, F | 1 |
| Hasebe, N; Jin, YT; Kido, S; Kikuchi, K; Natori, S; Ohta, T; Sato, M; Tsuji, S | 1 |
| Greenberg, B | 1 |
| Bruni, F; Carerj, S; Luzza, F; Rizzo, F | 1 |
19 review(s) available for angiotensin ii and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models.
Topics: Angiotensin II; Animals; Aorta; B-Lymphocytes; Cardiomegaly; Cell Movement; Constriction, Pathologic; Cytokines; Disease Models, Animal; Endomyocardial Fibrosis; Heart Failure; Humans; Hypertension; Mice; Monocytes; T-Lymphocytes; Time Factors; Ventricular Dysfunction, Left | 2018 |
The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction.
Topics: Angiotensin II; Brain; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Sympathetic Nervous System; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Large blood pressure variability and hypertensive cardiac remodeling--role of cardiac inflammation.
Topics: Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Fibrosis; Humans; Hypertension; Macrophages; Myocarditis; Myocardium; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sympathectomy; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease.
Topics: Aldosterone; Angiotensin II; Animals; Heart Ventricles; Humans; Renal Insufficiency, Chronic; Ventricular Dysfunction, Left | 2012 |
Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Heart Failure; Humans; Renin-Angiotensin System; Ventricular Dysfunction, Left | 2003 |
Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Agents; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proteinuria; Rats; Renin-Angiotensin System; Ventricular Dysfunction, Left | 2004 |
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Spironolactone; Ventricular Dysfunction, Left | 2004 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibody Formation; Collagen; Collagenases; Connective Tissue; Dinoprostone; Endomyocardial Fibrosis; Fibroblasts; Heart Failure; Humans; Hypertension; Matrix Metalloproteinase 1; Myocardial Infarction; Myocardium; Neurotransmitter Agents; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1995 |
Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Disease; Heart; Heart Failure; Humans; Myocardial Contraction; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1994 |
Effects of ACE inhibitors on coronary atherosclerosis and restenosis.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hypertrophy, Left Ventricular; Recurrence; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1994 |
Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Sympathetic Nervous System; Ventricular Dysfunction, Left | 1994 |
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Natriuretic Factor; Contraindications; Cough; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Polymorphism, Genetic; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1996 |
[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system].
Topics: Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Heart Failure; Humans; Hypertrophy, Left Ventricular; Neurotransmitter Agents; Norepinephrine; Renin; Stroke Volume; Systole; Ventricular Dysfunction, Left | 1997 |
Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Female; Fibrosis; Heart Failure; Humans; Myocardial Infarction; Myofibrils; Peptidyl-Dipeptidase A; Ventricular Dysfunction, Left | 1997 |
Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Clinical Trials as Topic; Heart; Humans; Myocardial Infarction; Myocardium; Necrosis; Renin-Angiotensin System; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 1997 |
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Pilot Projects; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1997 |
Ischemic cardiomyopathy and the cellular renin-angiotensin system.
Topics: Angiotensin II; Animals; Apoptosis; Cardiomyopathy, Dilated; Cell Survival; Cells, Cultured; Humans; Myocardial Ischemia; Myocardium; Rats; Renin-Angiotensin System; Sensitivity and Specificity; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2000 |
[Pathophysiology of congestive heart failure].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Atrial Natriuretic Factor; Cytokines; Heart Failure; Humans; Natriuretic Peptide, Brain; Neurosecretory Systems; Neurotransmitter Agents; Prognosis; Rats; Renin-Angiotensin System; Risk Factors; Swine; Ventricular Dysfunction, Left | 2002 |
6 trial(s) available for angiotensin ii and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial.
Topics: Aged; Aldosterone; Anaerobic Threshold; Angiotensin II; Cardiac Output, Low; Cardiac Volume; Echocardiography; Exercise; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Oxygen; Physical Endurance; Prospective Studies; Quality of Life; Single-Blind Method; Stroke Volume; Treatment Failure; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Pilot Projects; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1997 |
[The changes of PRA, ATII, ald, ET and ANP in patients with left ventricular diastolic heart failure and intervention with enalapril].
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Double-Blind Method; Enalaprilat; Endothelins; Female; Humans; Male; Middle Aged; Renin; Ventricular Dysfunction, Left | 1997 |
Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Cardiac Catheterization; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Indoles; Lactic Acid; Male; Middle Aged; Norepinephrine; Ventricular Dysfunction, Left; Ventricular Function, Left | 1999 |
Augmented responses of angiotensin I and II in patients with ischemic heart disease: relation to left ventricular function.
Topics: Aged; Angiotensin I; Angiotensin II; Exercise Test; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Pilot Projects; Renin-Angiotensin System; Stroke Volume; Sympathetic Nervous System; Ventricular Dysfunction, Left; Ventricular Function, Left | 2000 |
72 other study(ies) available for angiotensin ii and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Angiotensin IV attenuates diabetic cardiomyopathy
Topics: Angiotensin II; Animals; Apoptosis; Autophagy; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Forkhead Box Protein O1; Glucose; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Oxidative Stress; Quinolones; Signal Transduction; Streptozocin; Ventricular Dysfunction, Left | 2021 |
Cardiomyocyte-Specific
Topics: Angiotensin II; Animals; Cell Line; Endothelial Cells; Fibrosis; Heart; Heart Failure; In Vitro Techniques; Inflammation; Macrophages; Mice; Mice, Knockout; Myocardium; Myocytes, Cardiac; NF-kappa B; Protein Serine-Threonine Kinases; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2019 |
Mandibular Advancement Devices Prevent the Adverse Cardiac Effects of Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS).
Topics: Acrylic Resins; Angiotensin II; Animals; Cytokines; Echocardiography; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Heart; Male; Myocardium; Occlusal Splints; Polysomnography; Rabbits; RNA, Messenger; Sleep Apnea, Obstructive; Ventricular Dysfunction, Left | 2020 |
Intermedin alleviates pathological cardiac remodeling by upregulating klotho.
Topics: Angiotensin II; Animals; Aorta, Abdominal; Calcineurin; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cells, Cultured; Constriction; Disease Models, Animal; Fibrosis; Glucuronidase; Hypertrophy, Left Ventricular; Klotho Proteins; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Neuropeptides; Peptide Hormones; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Signal Transduction; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Diminazene; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Activators; Humans; Hypertension, Pulmonary; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Ventricular Dysfunction, Left | 2020 |
Chronic Naltrexone Therapy Is Associated with Improved Cardiac Function in Volume Overloaded Rats.
Topics: Angiotensin II; Animals; Disease Models, Animal; Heart Function Tests; Myocytes, Cardiac; Naltrexone; Narcotic Antagonists; Nerve Tissue Proteins; Rats; Rats, Wistar; Receptors, Opioid; Treatment Outcome; Ventricular Dysfunction, Left; Water Intoxication | 2021 |
Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Topics: Angiotensin II; Animals; Antifibrotic Agents; Benzhydryl Compounds; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Glucosides; Hypertrophy, Left Ventricular; Male; Myocardium; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |
ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
Topics: Angiotensin II; Animals; Aorta; Apelin Receptors; Arterial Pressure; Cardiotonic Agents; Constriction; Disease Models, Animal; Fibrosis; Forkhead Box Protein M1; Gene Expression Regulation; Heart Failure; HEK293 Cells; Humans; Hypertension; Hypertrophy, Left Ventricular; Infusions, Subcutaneous; Ligands; Male; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocardium; Peptide Hormones; Peptidyl-Dipeptidase A; Signal Transduction; Transfection; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Critical Role of ADAMTS2 (A Disintegrin and Metalloproteinase With Thrombospondin Motifs 2) in Cardiac Hypertrophy Induced by Pressure Overload.
Topics: ADAMTS Proteins; Angiotensin II; Animals; Biopsy, Needle; Cardiomegaly; Disease Models, Animal; Disintegrins; Gene Expression Regulation; Humans; Metalloproteases; Mice; Mice, Transgenic; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Random Allocation; Signal Transduction; Thrombospondins; Tissue Culture Techniques; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2017 |
The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Collagen; Fibrosis; Heart Function Tests; Immunohistochemistry; Male; Myocardial Infarction; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; RNA, Messenger; Ventricular Dysfunction, Left; Ventricular Remodeling | 2017 |
The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice.
Topics: Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Genetic Predisposition to Disease; Hypertension; Male; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Phenotype; Receptors, G-Protein-Coupled; Ventricular Dysfunction, Left; Ventricular Function, Left | 2018 |
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, Animal; Disease Progression; Echocardiography; Energy Metabolism; Fibrosis; Heart Failure; Hypertension; Immunohistochemistry; Male; Mice; Renin; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2018 |
G-Protein-Coupled Estrogen Receptor Agonist G1 Improves Diastolic Function and Attenuates Cardiac Renin-Angiotensin System Activation in Estrogen-Deficient Hypertensive Rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Cyclopentanes; Diastole; Disease Models, Animal; Estrogens; Female; Hypertension; Myocardium; Ovariectomy; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Quinolines; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Signal Transduction; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Neuroendocrine and haemodynamic changes in single-lead atrial pacing and dual-chamber pacing modes.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Flow Velocity; Cross-Over Studies; Endothelins; Female; Heart Atria; Heart Rate; Humans; Male; Middle Aged; Pacemaker, Artificial; Sick Sinus Syndrome; Time Factors; Ventricular Dysfunction, Left | 2013 |
Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling.
Topics: Angiotensin II; Animals; Aorta; Cardiomegaly; Echocardiography; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; TNF Receptor-Associated Factor 2; Up-Regulation; Ventricular Dysfunction, Left | 2014 |
Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.
Topics: Angiotensin II; Animals; Antibodies, Monoclonal; Aorta, Thoracic; Collagen Type I; Connective Tissue Growth Factor; Constriction, Pathologic; Fibroblasts; Gene Expression; Heart; Heart Failure; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Plasminogen Activator Inhibitor 1; Pressure; Reverse Transcriptase Polymerase Chain Reaction; Ventricular Dysfunction, Left; Ventricular Remodeling; Weight-Bearing | 2014 |
A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress.
Topics: Actins; Adrenergic beta-1 Receptor Agonists; Age Factors; Angiotensin II; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Excitation Contraction Coupling; Genetic Predisposition to Disease; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Mutation; Myocardial Contraction; Papillary Muscles; Phenotype; Phosphorylation; Troponin I; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2015 |
Full Expression of Cardiomyopathy Is Partly Dependent on B-Cells: A Pathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis.
Topics: Angiotensin II; Animals; Apoptosis; B-Lymphocytes; Cardiomyopathies; Collagen; Cytokines; Disease Models, Animal; Fibroblasts; Fibrosis; Genetic Predisposition to Disease; Heart Failure; Hypertrophy, Left Ventricular; Immunoglobulin G; Magnetic Resonance Imaging; Male; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, SCID; Myocardium; NG-Nitroarginine Methyl Ester; Phenotype; Sialic Acid Binding Ig-like Lectin 2; Signal Transduction; Sodium Chloride; Stroke Volume; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2016 |
Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice.
Topics: Angiotensin II; Animals; Animals, Newborn; Aortic Diseases; Basigin; Blood Proteins; Cells, Cultured; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinases; Mechanotransduction, Cellular; Mice, Knockout; Myocardium; Myocytes, Cardiac; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Transient Receptor Potential Melastatin 7 Cation Channel Kinase: New Player in Angiotensin II-Induced Hypertension.
Topics: Analysis of Variance; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Hypertension; Male; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Random Allocation; Reactive Oxygen Species; Risk Assessment; TRPM Cation Channels; Up-Regulation; Ventricular Dysfunction, Left | 2016 |
Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.
Topics: Age Factors; Angiotensin II; Animals; Blood Pressure; Chymases; Cromolyn Sodium; Crosses, Genetic; Diastole; Disease Models, Animal; Estrogens; Female; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Infusions, Subcutaneous; Mast Cells; Ovariectomy; Rats, Inbred BN; Rats, Inbred F344; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2016 |
Partial inhibition of activin receptor-like kinase 4 attenuates pressure overload-induced cardiac fibrosis and improves cardiac function.
Topics: Activin Receptors, Type I; Angiotensin II; Animals; Aorta; Apoptosis; Blood Pressure; Cardiomegaly; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Disease Models, Animal; Fibroblasts; Fibrosis; Haploinsufficiency; Heterozygote; Male; Mice; Myocardium; Myocytes, Cardiac; Signal Transduction; Smad2 Protein; Smad3 Protein; Stroke Volume; Transforming Growth Factor beta; Up-Regulation; Ventricular Dysfunction, Left | 2016 |
A Disintegrin and Metalloprotease-17 Regulates Pressure Overload-Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin β1.
Topics: ADAM17 Protein; Angiotensin II; Animals; Cardiomyopathy, Hypertrophic; Cells, Cultured; Disease Models, Animal; Disintegrins; Echocardiography, Doppler; Hypertension; Hypertrophy, Left Ventricular; Mice; Mice, Knockout; Myocytes, Cardiac; Proteolysis; Random Allocation; Rats; Ventricular Dysfunction, Left | 2016 |
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Topics: Angiotensin II; Animals; Antioxidants; Cyclic N-Oxides; Diastole; Disease Models, Animal; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spin Labels; Spironolactone; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2008 |
Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart.
Topics: Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Dogs; Echocardiography; Heart Failure; Hemodynamics; Male; Oxidative Stress; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Conventional therapy with an ACE inhibitor diminishes left ventricular dyssynchrony during the progression of heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Comorbidity; Disease Progression; Dogs; Heart Failure; Hemodynamics; Male; Norepinephrine; Ventricular Dysfunction, Left | 2010 |
Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Blotting, Western; Body Weight; Cardiomegaly; Echocardiography; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Heart; Hypertension; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Ventricular Dysfunction, Left | 2010 |
Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Male; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Inbred SHR; Receptors, G-Protein-Coupled; Renin; RNA, Messenger; Sodium Chloride, Dietary; Ventricular Dysfunction, Left; Ventricular Remodeling | 2010 |
Cardiac lymphatic obstruction impairs left ventricular function and increases plasma endothelin-1 and angiotensin II in rabbits.
Topics: Angiotensin II; Animals; Endothelin-1; Female; Heart Diseases; Lymphatic Diseases; Male; Rabbits; Stroke Volume; Ventricular Dysfunction, Left | 2009 |
Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Diastole; Echocardiography, Doppler, Pulsed; Fibrosis; Heart Atria; Heart Rate; Heart Ventricles; Hemodynamics; Hypercholesterolemia; Ivabradine; Oxidative Stress; Rabbits; Sinoatrial Node; Ventricular Dysfunction, Left | 2010 |
Intramyocardial BNP gene delivery improves cardiac function through distinct context-dependent mechanisms.
Topics: Adenoviridae; Angiotensin II; Animals; Collagen Type III; Disease Models, Animal; Fibrosis; Gene Transfer Techniques; Genetic Therapy; Humans; Hypertension; Ligation; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Organothiophosphorus Compounds; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis.
Topics: Analysis of Variance; Angiotensin II; Animals; Biomarkers; Blood Pressure; Bone Marrow Cells; Cardiomegaly; Cell Movement; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Diseases; Heart Rate; Hypertension; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Receptors, CCR2; Stem Cells; Stroke Volume; Time Factors; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2011 |
Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Coronary Vessels; Cyclic GMP; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Echocardiography; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Nitrates; Nitrites; Pyrroles; Random Allocation; Swine; Vasodilation; Ventricular Dysfunction, Left | 2011 |
Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure.
Topics: Angiotensin II; Animals; Body Weight; Brain; Brain Stem; Electrocardiography; Heart; Heart Failure; Infusions, Intraventricular; Losartan; Male; Mice; Mice, Inbred ICR; Models, Biological; Myeloid Differentiation Factor 88; Myocardial Infarction; NF-kappa B; Norepinephrine; Organ Size; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Toll-Like Receptor 4; Ventricular Dysfunction, Left | 2011 |
Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium; Cardiotonic Agents; Cell Line; Collagen; Cyclopentanes; Echocardiography, Doppler; Estrogens; Female; Gene Expression Regulation; Genotype; Hypertrophy, Left Ventricular; Injections, Subcutaneous; Mice; Myocytes, Cardiac; NADPH Oxidase 4; NADPH Oxidases; Natriuretic Peptide, Brain; Ovariectomy; Phenotype; Quinolines; Rats; Rats, Inbred Lew; Rats, Transgenic; Receptors, G-Protein-Coupled; Renin; RNA, Messenger; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Hypertrophy; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocytes, Cardiac; Neovascularization, Physiologic; Olmesartan Medoxomil; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Tetrazoles; Thrombospondin 1; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left | 2012 |
The role of renin angiotensin system intervention in stage B heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Renin-Angiotensin System; Signal Transduction; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Failure; Heart Rate; Immunohistochemistry; In Situ Nick-End Labeling; Ivabradine; Male; Metoprolol; Mice; Mice, Inbred C57BL; Multivariate Analysis; Random Allocation; Sensitivity and Specificity; Statistics, Nonparametric; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway.
Topics: Angiotensin II; Animals; Animals, Newborn; Cell Proliferation; Cells, Cultured; Chronic Disease; Collagen; Compliance; Echocardiography; Fibroblasts; Fibrosis; Gene Silencing; Hemodynamics; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Myocardial Infarction; Myocardium; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Treatment Outcome; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2012 |
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Cytokines; Extracellular Matrix; Heart Failure; Heart Function Tests; Hydralazine; Male; Mice; Mice, Inbred C57BL; Myocarditis; Myocardium; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Sildenafil Citrate; Sulfones; Vasoconstrictor Agents; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression.
Topics: Angiotensin II; Animals; Cells, Cultured; Collagen; Disease Models, Animal; Down-Regulation; Fibrosis; Heart Failure; Heart Ventricles; Hypertension; Leupeptins; Male; Proteasome Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Signal Transduction; Transforming Growth Factor beta1; Ubiquitin; Ventricular Dysfunction, Left | 2013 |
Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Dipeptides; Disease Models, Animal; Fibrosis; Hypertrophy, Left Ventricular; Imidazoles; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Microcirculation; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptor, Notch1; Tetrazoles; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Increased preload directly induces the activation of heat shock transcription factor 1 in the left ventricular overloaded heart.
Topics: Angiotensin II; Animals; Cardiomegaly; DNA-Binding Proteins; Epinephrine; Gene Expression Regulation; Heat Shock Transcription Factors; Heat-Shock Proteins; Hemodynamics; Male; Norepinephrine; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Transcription Factors; Vasopressins; Ventricular Dysfunction, Left | 2002 |
[Addition of an angiotensin II receptor blocker to maximal dose of ACE inhibitors in heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Data Interpretation, Statistical; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Losartan; Male; Middle Aged; Oxygen Consumption; Time Factors; Ventricular Dysfunction, Left | 2002 |
Impaired coronary flow and left ventricular dysfunction after mechanical recanalization in acute myocardial infarction: role of neurohumoral activation?
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II; Biomarkers; Coronary Angiography; Coronary Circulation; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Neurotransmitter Agents; Ventricular Dysfunction, Left | 2002 |
Improved neurohormonal markers of ventricular function after restoring sinus rhythm by the Maze procedure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Atrial Fibrillation; Atrial Natriuretic Factor; Chronic Disease; Cryosurgery; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Postoperative Complications; Vasopressins; Ventricular Dysfunction, Left; Ventricular Function, Left | 2003 |
Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.
Topics: Angiotensin II; Animals; Chymases; Collagen Type I; Collagen Type III; Diastole; Disease Models, Animal; Disease Progression; Dogs; Enzyme Inhibitors; Fibrosis; Heart Failure; Hemodynamics; Mast Cells; Myocardium; Peptidyl-Dipeptidase A; RNA, Messenger; Serine Endopeptidases; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2003 |
Induction of left ventricular remodeling and dysfunction in the recipient heart after donor heart myocardial infarction: new insights into the pathologic role of tumor necrosis factor-alpha from a novel heterotopic transplant-coronary ligation rat model.
Topics: Angiotensin II; Animals; Disease Models, Animal; Heart Transplantation; Immunohistochemistry; Male; Rats; Rats, Inbred Lew; Receptors, Tumor Necrosis Factor; Stroke Volume; Transplantation, Heterotopic; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Body Weight; Capillaries; Cytokines; Diabetic Angiopathies; Heme Oxygenase (Decyclizing); Immunohistochemistry; Male; Matrix Metalloproteinases; Organ Size; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-2; Ventricular Dysfunction, Left | 2003 |
Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Angiotensin II; Animals; Chemokine CCL2; Cytokines; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Genetic Therapy; Heart Failure; Humans; Immunohistochemistry; Male; Matrix Metalloproteinases; Mice; Muscle, Skeletal; Myocardial Infarction; Myocardium; Sequence Deletion; Survival Rate; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
Topics: Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Baroreflex; Brain; DNA, Antisense; Genes, Synthetic; Glial Fibrillary Acidic Protein; Heart Rate; Hypothalamus; Injections, Intraventricular; Male; Myocardial Infarction; Organ Size; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reflex, Abnormal; Renin-Angiotensin System; Stress, Psychological; Stroke Volume; Sympathetic Nervous System; Transgenes; Ventricular Dysfunction, Left; Ventricular Remodeling | 2004 |
The angiotensin II type 2 receptor and improved adjacent region function post-MI.
Topics: Angiotensin II; Animals; Collagen; Contrast Media; Disease Models, Animal; Gadolinium DTPA; Heart Ventricles; Image Processing, Computer-Assisted; Magnetic Resonance Imaging, Cine; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardial Contraction; Myocardial Infarction; Myocytes, Cardiac; Receptor, Angiotensin, Type 2; Stroke Volume; Systole; Ventricular Dysfunction, Left; Ventricular Remodeling | 2005 |
Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats.
Topics: Aging; Angiotensin II; Animals; Diastole; Growth Hormone; Heart; Hormone Replacement Therapy; Myocardium; Rats; Rats, Inbred BN; Rats, Inbred F344; Time Factors; Ventricular Dysfunction, Left | 2006 |
Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Connective Tissue Growth Factor; Diastole; Gene Expression; Heart Failure; Heart Ventricles; Hypertension; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Ion Channels; Lung; Male; Membrane Transport Proteins; Mitochondrial Proteins; Myocardium; NADPH Oxidases; Natriuretic Peptide, Brain; Organ Size; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta; Uncoupling Protein 2; Ventricular Dysfunction, Left | 2006 |
Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha.
Topics: Adenoviridae; Adiponectin; AMP-Activated Protein Kinase Kinases; Angiotensin II; Animals; Fibrosis; Heart Diseases; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 3; Myocardial Contraction; Myocardium; Myocytes, Cardiac; PPAR alpha; Protein Kinases; Reactive Oxygen Species; Ventricular Dysfunction, Left | 2008 |
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.
Topics: Actins; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cells, Cultured; Collagen; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Imidazoles; Myocardial Infarction; Myocytes, Cardiac; Neoplasm Proteins; Organ Size; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Baroreflex; Brain; Fibrosis; Hemodynamics; Indoles; Infusions, Intravenous; Injections, Subcutaneous; Kidney; Lisinopril; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Renin-Angiotensin System; Sympathetic Nervous System; Ventricular Dysfunction, Left | 2008 |
Evidence for impaired endothelium dependent vasodilation in experimental left ventricular dysfunction.
Topics: Acetylcholine; Adenosine; Angiotensin II; Animals; Autonomic Nerve Block; Doxorubicin; Hindlimb; Injections, Intra-Arterial; Ischemia; Models, Cardiovascular; Nitroprusside; Norepinephrine; Rabbits; Vasoconstriction; Vasodilation; Ventricular Dysfunction, Left | 1994 |
Noninvasive evaluation of contractile state by left ventricular dP/dtmax divided by end-diastolic volume using continuous-wave Doppler and M-mode echocardiography.
Topics: Aged; Angiotensin II; Cardiac Catheterization; Dobutamine; Echocardiography; Echocardiography, Doppler; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mitral Valve Insufficiency; Regression Analysis; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 1994 |
Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Benzeneacetamides; Cardiac Pacing, Artificial; Coronary Circulation; Electrocardiography; Epinephrine; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Propanolamines; Sympathomimetics; Ventricular Dysfunction, Left | 1998 |
Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.
Topics: 6-Ketoprostaglandin F1 alpha; Aging; Angiotensin II; Animals; Growth Hormone; Heart; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Oligopeptides; Protective Agents; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left | 1998 |
Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Biomarkers; Endothelin-1; Female; Humans; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Radioimmunoassay; Retrospective Studies; Severity of Illness Index; Stroke Volume; Survival Rate; Ventricular Dysfunction, Left; Ventricular Pressure | 1999 |
Role of angiotensin II in sympathetic nervous system induced left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Heart Rate; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sympathetic Nervous System; Vasoconstrictor Agents; Ventricular Dysfunction, Left; Veratrine | 1999 |
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Heart Failure; Humans; Middle Aged; Regression Analysis; Renin-Angiotensin System; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2000 |
Use of angiotensin II stress pulsed tissue Doppler imaging to evaluate regional left ventricular contractility in patients with hypertrophic cardiomyopathy.
Topics: Analysis of Variance; Angiotensin II; Blood Flow Velocity; Cardiomyopathy, Hypertrophic; Case-Control Studies; Echocardiography, Doppler, Pulsed; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2000 |
Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula.
Topics: Angiotensin II; Animals; Aorta; Arteriovenous Fistula; Cardiomegaly; Chymases; Disease Models, Animal; Genetic Variation; Male; Mice; Mice, Knockout; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Serine Endopeptidases; Up-Regulation; Vena Cava, Inferior; Ventricular Dysfunction, Left | 2001 |
Load versus humoral activation in the genesis of early hypertensive heart disease.
Topics: Angiotensin II; Animals; Catecholamines; Diastole; Disease Models, Animal; Dogs; Endothelin-1; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Natriuretic Peptide, Brain; Propranolol; Renin; Systole; Ventricular Dysfunction, Left | 2001 |
Cardiac and renal effects of growth hormone in volume overload-induced heart failure: role of NO.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cyclic GMP; Enzyme Inhibitors; Growth Hormone; Heart; Heart Failure; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Kidney; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Organ Size; Rats; Rats, Wistar; Recombinant Proteins; RNA, Messenger; Ventricular Dysfunction, Left | 2002 |
Left ventricular structure and diastolic function in subjects with two hypertensive parents.
Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Blood Pressure; Case-Control Studies; Catecholamines; Electrocardiography; Family Health; Female; Humans; Hypertension; Insulin Resistance; Male; Parents; Renin; Ventricular Dysfunction, Left; Ventricular Remodeling | 2001 |
Effects of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor blocker on cardiac dysfunction induced by isoproterenol in dogs.
Topics: Adrenergic beta-Agonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Creatine Kinase; Creatine Kinase, MB Form; Dogs; Female; Heart Diseases; Hemodynamics; Isoenzymes; Isoproterenol; L-Lactate Dehydrogenase; Lipid Peroxides; Male; Receptor, Angiotensin, Type 1; Ventricular Dysfunction, Left | 2001 |
Treatment of heart failure: state of the art and prospectives.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; Drug Therapy; Endothelins; Heart Failure; Humans; Norepinephrine; Review Literature as Topic; Spironolactone; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left | 2001 |